H&T Presspart have confirmed attendance for the Management Forum Dry Powder Inhaler Conference for Pharmaceutical and Medical Device Professionals on the 19th and 20th June 2019 at The Rembrandt Hotel, London.

The second generation of DPIs have become established on the market and have been a great success story in improving inhaled drug delivery. However, there are now technical and regulatory issues with ‘generic’ inhalers and their approval. The development of triple therapies is well underway and these bring about their own challenges of formulation and bioequivalence.

This conference will address many of the issues around generic inhalers, provide case studies of bioequivalence testing, focus on the difficult formulation challenges and the strategies used so that they may be overcome, and discuss in-depth patient and human factor issues when developing a DPI to gain regulatory approval.

Dr Anselm Ebert, H&T Presspart’s Business Development Director, is proudly speaking at this event alongside George Bostock (Cambridge Design Partnership). They shall be discussing the opportunities and challenges in the design of a high-performance unit-dose DPI, design opportunities and challenges for a ‘fit for purpose’ capsule-based DPI and prototyping challenges faced with DPIs.

In developing markets, where demand for respiratory treatments is growing rapidly, there’s an increasing need to offer more choice to patients who use a dry powder inhaler (DPI). As the world’s leading manufacturer of respiratory drug delivery components and devices, this conference should provide great insight into the market picture today and will address many of the issues around generic inhalers, further supporting Presspart’s development and manufacture of their own DPI device.

If you would like to get in touch with any questions about the event, please visit our contact page for more information.